Where to meet us
Our most recent publications
Kuhler TC., Bujar M., McAuslane N., Liberti L. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016. BMJ Open 2019;9:e028677
Bujar M, McAuslane N, Walker S, Salek S. The reliability and relevance of a quality of decision- making instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for use during the lifecycle of medicines. Front Pharmacol. 2019;10:17. Published 2019 Jan 23. doi:10.3389/fphar.2019.00017
Mashaki Ceyhan E, Gürsöz H, Alkan A, Coşkun H, Koyuncu O, Walker S. The Turkish Medicines and Medical Devices Agency: Comparison of its registration process with Australia, Canada, Saudi Arabia, and Singapore. Front Pharmacol. 2018;9 DOI=10.3389/fphar.2018.